Peptides
NAD+ (Nicotinamide Adenine Dinucleotide)
Also called NAD · Nicotinamide Adenine Dinucleotide
NAD+ infusions are marketed for energy, clearer thinking and healthy aging. Human studies have measured changes in NAD-related blood markers, but that is not the same as proving a lasting improvement in energy or reversing aging. Time, cost and infusion tolerability are practical considerations.
Dosage & duration
Grant 2019 human pilot; a studied infusion, not a recommended wellness cycle.
Single-infusion study
Published example · product-specific- Dose
- 750 mg IV
- How often
- One infusion over 6 hours
- How long
- One study visit; metabolites followed for 8 hours
Does not define an IM/SC dose or a repeated anti-aging schedule.
Sources: 1
Why people look into it
Energy and clearer thinking are the appeal
NAD+ infusions are marketed around how people hope to feel; blood-marker changes are a different result.
-
Daily function
Energy and mental clarity need direct measurement. The cited infusion pilot measured metabolites.
-
Healthy aging
An eight-hour observation cannot establish lasting benefit or reversal of aging.
-
The practical cost
Infusion time, expense and tolerability matter when a lasting benefit has not been established.
What people hope to feel
The appeal is an energy or mental-clarity boost. NAD+ plays an essential part in cell chemistry, but more NAD-related material in blood is not a direct measure of how energetic someone feels.
What the frequently cited study tested
The 2019 pilot gave eight men one six-hour infusion and three men saline. It measured metabolites over eight hours; it did not establish a maintenance course or anti-aging outcome.
Product quality matters
FDA has received reports of chills, shaking, vomiting and fatigue after compounded NAD+ injectables, consistent with excessive endotoxins. A wellness ingredient suitable for oral use is not automatically suitable for injection.
Dose references and context Existing reported protocols; not personal dosing instructions
This older catalog material includes research and community reports. It has not all been source-checked in this page update and should not be treated as a dosing recommendation.
Metabolome pilot — research context
750 mg · Intravenous infusion · One infusion over 6 hours
Eight treated participants; not a wellness-treatment recommendation or long-term schedule.
Model details: NAD+ (Nicotinamide Adenine Dinucleotide) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 12 hours
- Absorption half-life assumed
- 3 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Infusion is not a bolus, oral or SC formulation. Endogenous baseline and rapid uptake/metabolism prevent assigning one observed mixture response as a per-dose Cmax. The 12-hour timing remains illustrative.
- Grant et al. 2019: human NAD+ metabolome infusion pilot
Human infusion study observed no early plasma rise followed by later changes in NAD+ and metabolites; measured metabolites are separate analytes.
nad-plus-relative-timing-2026-10 · version 1
Common questions
Does an increase in blood NAD+ prove better energy?
No. A biochemical change and a meaningful change in daily function are different outcomes.
Is an IV dose transferable to a small subcutaneous shot?
No. Route, concentration and administration time differ; the six-hour study does not supply that conversion.
Sources Labels, studies and notes behind this guide
Catalog evidence: Other human research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- Common marketing goals, not guaranteed results.
- Practical burden
- The named study used six hours, not a quick injection.
- 1. Grant et al.: IV NAD+ metabolome pilot
Eleven men: eight received 750 mg IV NAD+ over six hours, three saline. Followed plasma/urine metabolites over eight hours; not an anti-aging, addiction-treatment or functional-outcome trial.
- 2. FDA: ingredients for sterile NAD+ compounding
FDA reported chills, shaking, vomiting and fatigue after NAD+ injectables, consistent with excessive endotoxins; food-grade starting material is not automatically suitable for sterile drugs.
- 3. Grant et al. 2019: human NAD+ metabolome infusion pilot
Human infusion study observed no early plasma rise followed by later changes in NAD+ and metabolites; measured metabolites are separate analytes.
Keep reading
Related compounds and examples
Related compounds
L-Carnitine (Injectable)
Injectable L-carnitine is discussed for fat loss, workout pumps and performance. It helps the body handle fatty acids, but that role does not mean an injection automatically burns body fat. The approved IV medicine treats specific deficiency situations; bodybuilding use is a different context.
Glutathione
Glutathione for skin and antioxidant goals: oral study doses, injection trade-offs and why a higher blood level is not a guaranteed detox or cosmetic result.
Pinealon
Pinealon for memory and brain-aging questions: capsule versus injection amounts, realistic expectations and what its research actually measures.